NASDAQ$HRTX
Heron Therapeutics Inc · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
Heron Therapeutics reported net product sales increase driven by oncology care franchise and ZYNRELEF, with APONVIE approved by the FDA.
Heron Therapeutics announced its Q3 2022 financial results, with net product sales of $26.6 million, an increase compared to $23.2 million for the same period in 2021. The company's net loss was $41.9 million, or $0.38 per share. The FDA approved APONVIE, and the company plans a U.S. launch in Q1 2023. ZYNRELEF unit demand grew 18% over the prior quarter, and oncology care franchise net product sales grew 13% over the prior year.
- APONVIE was approved by the FDA, with a U.S. launch planned for Q1 2023.
- ZYNRELEF unit demand grew 18% over the prior quarter in Q3 2022.
- Oncology Care Franchise net product sales grew 13% over the prior year in Q3 2022.
- A $75 million private placement was completed to strengthen the balance sheet.
Headline financials
Revenue & EPS history
Heron Therapeutics · Revenue · Quarterly
$26.6M
Revenue by segment
Heron Therapeutics · $26.6M total across 3 segments · Q3 2022
- CINVANTI$21.2M+17.8%79.7%
- ZYNRELEF$2.7M+28.6%10.2%
- SUSTOL$2.7M-12.9%10.2%
Forward guidance
Heron expects fourth quarter 2022 ZYNRELEF net product sales to increase in the range of 30% to 40% over the prior quarter and full-year 2022 net product sales for the oncology care franchise of $93 million to $95 million.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2022
-0.9%
Avg return
Earnings day
+0.6%
Avg return
5 days after
+1.4%
Avg return
30 days after
48%
30 / 63 earnings
Positive
+57.6%
Q3 2023
Best reaction
-42.9%
Q1 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -21.1% | -29.8% | -66.3% | |
| Q4 2025 | +12.4% | +6.5% | -27.8% | |
| Q3 2025 | -1.8% | -6.8% | +11.0% | |
| Q1 2025 | +13.8% | -0.9% | -6.1% | |
| Q4 2024 | +19.9% | +49.1% | +32.2% | |
| Q3 2024 | -34.2% | -35.3% | -13.0% | |
| Q2 2024 | -24.0% | -24.7% | -31.6% | |
| Q1 2024 | +6.0% | -2.5% | +27.8% | |
| Q4 2023 | +24.9% | +27.0% | +22.0% | |
| Q3 2023 | +57.6% | +98.2% | +230.9% | |
| Q2 2023 | +3.4% | +1.9% | -21.6% | |
| Q1 2023 | -42.9% | -48.6% | -49.4% | |
| Q4 2022 | -3.3% | -18.3% | +40.1% | |
| Q3 2022 | -12.0% | +0.6% | -20.5% | |
| Q2 2022 | +31.7% | +48.5% | +33.6% | |
| Q1 2022 | -14.8% | -12.7% | -34.3% | |
| Q4 2021 | -23.8% | -29.7% | -24.6% | |
| Q3 2021 | +0.8% | +10.1% | -24.0% | |
| Q2 2021 | -0.3% | -6.4% | -1.4% | |
| Q1 2021 | +11.1% | -16.7% | -11.2% | |
| Q4 2020 | +1.1% | +1.3% | -14.7% | |
| Q3 2020 | -5.1% | -0.1% | +1.5% | |
| Q2 2020 | -9.4% | -8.3% | -18.8% | |
| Q1 2020 | +2.4% | +7.2% | +34.1% | |
| Q4 2019 | -1.0% | -11.4% | -41.6% | |
| Q3 2019 | -2.3% | +4.8% | +24.1% | |
| Q2 2019 | +0.5% | +10.3% | +10.3% | |
| Q1 2019 | +6.3% | +7.0% | +4.6% | |
| Q4 2018 | -1.4% | -1.8% | -15.3% | |
| Q3 2018 | +3.8% | -4.6% | -8.1% | |
| Q2 2018 | +2.5% | +1.8% | -2.6% | |
| Q1 2018 | +1.2% | +4.3% | +0.3% | |
| Q4 2017 | -10.2% | -6.2% | +21.9% | |
| Q3 2017 | -0.3% | +1.9% | -4.2% | |
| Q2 2017 | -1.6% | -0.6% | +0.9% | |
| Q1 2017 | -9.3% | -8.9% | -13.7% | |
| Q4 2016 | +0.4% | +3.2% | +6.5% | |
| Q3 2016 | +13.3% | +7.7% | +7.3% | |
| Q2 2016 | +5.1% | +8.0% | -2.4% | |
| Q1 2016 | -14.9% | — | — | |
| Q3 2015 | -0.5% | — | — | |
| Q2 2015 | -1.5% | — | — | |
| Q1 2015 | +1.4% | — | — | |
| Q4 2014 | +5.4% | — | — | |
| Q3 2014 | -5.8% | — | — | |
| Q2 2014 | -0.1% | — | — | |
| Q1 2014 | +1.1% | — | — | |
| Q4 2013 | +3.7% | — | — | |
| Q3 2013 | +2.2% | — | — | |
| Q2 2013 | -2.2% | — | — | |
| Q1 2013 | +6.8% | — | — | |
| Q4 2012 | -2.9% | — | — | |
| Q3 2012 | -3.3% | — | — | |
| Q2 2012 | -5.9% | — | — | |
| Q1 2012 | +2.3% | — | — | |
| Q4 2011 | +18.2% | — | — | |
| Q3 2011 | +0.0% | — | — | |
| Q2 2011 | +3.6% | — | — | |
| Q1 2011 | +5.3% | — | — | |
| Q4 2010 | -21.3% | — | — | |
| Q3 2010 | -26.9% | — | — | |
| Q2 2010 | -4.7% | — | — | |
| Q1 2010 | -12.8% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro